Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
13 déc. 2021 07h00 HE
|
Autolus Therapeutics plc
- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study - Obe-cel response and safety data from the Phase 1b portion of the FELIX study...
Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
06 déc. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
15 nov. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
10 nov. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
08 nov. 2021 02h00 HE
|
Autolus Therapeutics plc
– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
04 nov. 2021 09h01 HE
|
Autolus Therapeutics plc
- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
03 nov. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
25 oct. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
16 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
15 sept. 2021 07h00 HE
|
Autolus Therapeutics plc
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...